Study: THC and CBD May Reduce Agitation in Advanced Dementia Patients

A clinical trial involving 120 patients demonstrated promising results within the first weeks, showing that a combination of THC and CBD significantly reduces agitation in individuals with Alzheimer's disease and other advanced-stage dementia forms. The LiBBY study, a phase clinical trial, provides evidence-based data supporting cannabinoid therapy as a potential therapeutic intervention for behavioral symptoms in neurodegenerative conditions. These findings are particularly significant for caregivers and patients seeking non-pharmacological or complementary approaches to manage distressing behavioral symptoms. The early positive outcomes suggest cannabinoids may offer relief where traditional treatments have limited efficacy, opening new possibilities for dementia care in Puerto Rico and beyond.